English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

ShangPharma Forms mAb Partnership with Hengrui Medicine

Sep. 14, 2011

ShangPharma, a Shanghai CRO, announced on September 15, 2011 that it will partner with Jiangsu Hengrui Medicine Co. to develop novel therapeutic monoclonal antibodies (mAbs).
Under the partnership’s framework, ShangPharma will head pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and preformulation studies, while Hengrui will lead drug development for the mAb.